Search

Displaying results 2631 - 2640 of 10000 in total
  1. Target

    Target of rapamycin complex 2 subunit MAPKAP1

    go.drugbank.com/bio_entities/BE0018900
    TargetHumans

    Within the mTORC2 complex, MAPKAP1/SIN1 acts as a substrate adapter which recognizes and binds AGC protein kinase family members for phosphorylation by MTOR (PubMed:21806543, PubMed:28264193). mTORC2 plays … Inhibits HRAS and KRAS independently of mTORC2 complex (PubMed:17303383, PubMed:34380736, PubMed:35522713).

    Polypeptides: Target of rapamycin complex 2 subunit MAPKAP1Synonyms: SIN1
  2. Drug

    Foscarbidopa

    go.drugbank.com/drugs/DB16171
    Approved

    Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult

    Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  3. Indication

    Extrapyramidal Symptoms

    go.drugbank.com/conditions/DBCOND0037190
    Drugs: Biperiden · Bornaprine
    Synonyms: Extrapyramidal sign, Extrapyramidal sign, NOS
  4. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    [L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. … [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499]

    Categories: Complex Mixtures
  5. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.

    Products: AZANIL 40MG/ML INJECTION
  6. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.

  7. Target

    Integrase, catalytic core

    go.drugbank.com/bio_entities/BE0003386
    TargetNitrosomonas europaea (strain ATCC 19718 / NBRC 14298)

    Polypeptides: Integrase, catalytic core
  8. Target

    Neurocan core protein

    go.drugbank.com/bio_entities/BE0004512
    TargetHumans

    May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM). Chondroitin sulfate proteoglycan; binds to hyaluronic acid

    Polypeptides: Neurocan core protein
  9. Target

    Versican core protein

    go.drugbank.com/bio_entities/BE0004606
    TargetHumans

    May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid

    Polypeptides: Versican core proteinSynonyms: Chondroitin sulfate proteoglycan core protein 2
  10. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.